Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) is a late-stage specialty pharmaceutical company founded in 2018 and based in Ashburn, Virginia, focused exclusively on rare and orphan dermatologic diseases. Its lead program, QRX003 — a topical serine protease inhibitor lotion for Netherton syndrome — holds Orphan Drug Designation in the US, EU, and Japan plus FDA Fast Track and Rare Pediatric Disease designations, and received FDA conditional approval of QYLEKI as its proposed brand name in June 2026. The company submitted the first-ever IND for Peeling Skin Syndrome (FDA-cleared July 2026) and is advancing a topical rapamycin platform (QRX009) toward clinical testing across Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. As of June 30, 2026 the company held approximately $10.8 million in cash and marketable securities, which management stated would fund operations into 2027.